ArticleNature communications2022
Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 130 citations in OpenAlex.
- The bacteriophage transcription factor Gp53 suppresses cell division and regulates Pseudomonas aeruginosa physiology.Communications biology · 2026Article
- Balancing of immune activation and suppression during phage infection.bioRxiv : the preprint server for biology · 2026Article
- Phage Therapy as an Alternative Strategy Against Pseudomonas aeruginosa: A Narrative Review of Preclinical and Clinical Evidence.MicrobiologyOpen · 2026Review
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Peptoid-based antimicrobial strategies against polymyxin-resistant Gram-negative bacteria.Journal of applied microbiology · 2026Article
- Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.Molecular biotechnology · 2026Review
- PhageCGRNet: Integrating Chaos Game Representation of Genomes with Convolutional Neural Network for accurate phage host classification prediction.PLoS computational biology · 2026Article
- Phage cocktails containing a dual-receptorApplied and environmental microbiology · 2026Article
- Investigation of the therapeutic efficacy and resistance mechanisms of lytic phages targeting ST218 KL57 CR-hvKP.mSystems · 2026Article
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Enzymes-enhanced antibiotic therapy reduces biofilms to undetectable levels in an implant-associated infection model.NPJ biofilms and microbiomes · 2026Article
- Phage cocktails: state-of-the-art technologies and strategies for effective design.FEMS microbiology reviews · 2026Review
- Multiomics Approaches for Bacteriophage-Based Biocontrol Applications: A Review of Metabolomics, Transcriptomics, and Proteomics.BioMed research international · 2026Review
- Characterization of a newly isolated broad-host-range lytic phage WEN7 against multidrug-resistant clinicalFrontiers in microbiology · 2026Article
- Lytic bacteriophages targeting carbapenem-resistant Klebsiella pneumoniae isolated in a resource-limited Zambian laboratory.Access microbiology · 2026Article
- Next-generation bacteriophage therapeutic systems: CRISPR-based engineering, near-infrared bioimaging, and precision strategies for treating multidrug-resistant and extensively drug-resistant bacterial infections.Frontiers in microbiology · 2026Review
- Phage therapy of perinephric abscess in kidney transplantation recipients caused by drug-resistantmLife · 2025Article
- Cefiderocol as a Successful Therapy for Osteomyelitis Due to XDRAntibiotics (Basel, Switzerland) · 2025Article
- Phage Therapy for Bone and Joint Infections: Towards Clinical Translation.Antibiotics (Basel, Switzerland) · 2025Review
- A novel broad host range phage phiA85 displays a synergistic effect with antibiotics targeting carbapenem-resistantMicrobiology spectrum · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone and joint infections (BJI) are one of the most difficult-to-treat bacterial infection, especially in the era of antimicrobial resistance. Lytic bacteriophages (phages for short) are natural viruses that can selectively target and kill bacteria. They are considered to have a high therapeutic potential for the treatment of severe bacterial infections and especially BJI, as they also target biofilms. Here we report on the management of a patient with a pandrug-resistant Pseudomonas aeruginosa spinal abscess who was treated with surgery and a personalized combination of phage therapy that was added to antibiotics. As the infecting P. aeruginosa strain was resistant to the phages developed by private companies that were contacted, we set up a unique European academic collaboration to find, produce and administer a personalized phage cocktail to the patient in due time. After two surgeries, despite bacterial persistence with expression of small colony variants, the patient healed with local and intravenous injections of purified phages as adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.